1,947
Views
1
CrossRef citations to date
0
Altmetric
Coronavirus – Letters

Adjudicating the logistics of COVID-19 vaccine boosters from a global perspective

ORCID Icon, ORCID Icon &
Article: 2020572 | Received 21 Oct 2021, Accepted 16 Dec 2021, Published online: 13 Jan 2022

References

  • Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, Cravioto A, Rees H, Higgins JPT, Boutron I, et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021;398:1377–3. doi:10.1016/S0140-6736(21)02046-8.
  • Priyanka OPC, Singh I. Protective immunity against COVID-19: unravelling the evidences for humoral vs. cellular components. Travel Med Infect Dis. 2020;39:101911. doi:10.1016/j.tmaid.2020.101911.
  • Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, Blane B, Bonsall D, Cicconi P, Charlton N, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351–62. doi:10.1016/S0140-6736(21)00628-0.
  • Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384:80–82. doi:10.1056/NEJMc2032195.
  • Choi A, Koch M, Wu K, Ma L, Hill A, Nunna N, Huang W, Oestreicher J, Colpittis T, Bennet H, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021. doi:10.1038/s41591-021-01527-y.
  • Choudhary OP, Choudhary P, Singh I. India’s COVID-19 vaccination drive: key challenges and resolutions. Lancet Infect Dis. 2021;21:1483–84. doi:10.1016/S1473-3099(21)00567-3.
  • European Centre for Disease Prevention and Control. Interim public health considerations for the provision of additional COVID-19 vaccine doses. Stockholm (Sweden): ECDC; Published 2021 Sept 1 [accessed 2021 Oct 20]. https://www.ecdc.europa.eu/en/publications-data/covid-19-public-health-considerations-additional-vaccine-doses.
  • Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Levin EG, Rubin C, Indenbaum V, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385:1474–84. doi:10.1056/NEJMoa2109072.
  • Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizeahi B, Alroy-Preis S, Ash N, Milo R, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385:1393–400. doi:10.1056/NEJMoa2114255.
  • Whitaker H, Tsang R, Byford R, Andrews NJ, Sherlock J, Pillai PS, Williams J, Button E, Canpbell H, Sinnathamby M, et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. 2021 [accessed 2021 Oct 20]. https://khub.net/documents/135939561/430986542/RCGP+VE+riskgroups+paper.pdf/a6b54cd9-419d-9b63-e2bf-5dc796f5a91f.
  • Chagla Z, Pai M. COVID-19 boosters in rich nations will delay vaccines for all. Nat Med. 2021;27:1659–60. doi:10.1038/s41591-021-01494-4.
  • Editorial. COVID-19 vaccine equity and booster doses. Lancet Infect Dis. 2021;21(9):1193. doi:10.1016/S1473-3099(21)00486-2.